| __timestamp | Bio-Techne Corporation | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 302156000 |
| Thursday, January 1, 2015 | 119401000 | 402271000 |
| Friday, January 1, 2016 | 140879000 | 476593000 |
| Sunday, January 1, 2017 | 199243000 | 554336000 |
| Monday, January 1, 2018 | 240636000 | 604353000 |
| Tuesday, January 1, 2019 | 264359000 | 680924000 |
| Wednesday, January 1, 2020 | 260583000 | 737669000 |
| Friday, January 1, 2021 | 324951000 | 759375000 |
| Saturday, January 1, 2022 | 372766000 | 854009000 |
| Sunday, January 1, 2023 | 378378000 | 937300000 |
| Monday, January 1, 2024 | 396826000 | 1009025000 |
Cracking the code
In the ever-evolving biotech industry, understanding financial trends is crucial. Over the past decade, Bio-Techne Corporation and BioMarin Pharmaceutical Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BioMarin's SG&A expenses surged by over 200%, peaking at approximately 937 million in 2023. In contrast, Bio-Techne's expenses grew by a remarkable 550%, reaching nearly 397 million in 2024. This divergence highlights BioMarin's aggressive expansion strategy compared to Bio-Techne's more measured approach. Notably, BioMarin's expenses consistently outpaced Bio-Techne's, reflecting its larger scale and broader market reach. However, the data for 2024 is incomplete for BioMarin, indicating potential shifts in strategy or reporting. These insights underscore the dynamic nature of financial management in the biotech sector, offering valuable lessons for investors and industry stakeholders.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Vericel Corporation
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Mesoblast Limited
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends